Company profile
GALECTIN THERAPEUTICS INC
NASDAQ:GALTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BELAPECTIN | phase2_3 | — | 6 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00388700 | phase2 | withdrawn | 2006-10-01 | 2009-06-01 | Galectin Therapeutics Inc. | A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer |
| NCT02407041 | phase2 | completed | 2015-09-01 | 2018-03-01 | Galectin Therapeutics Inc. | An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis |
| NCT02421094 | phase2 | completed | 2015-09-01 | 2016-09-27 | Galectin Therapeutics Inc. | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis |
| NCT02462967 | phase2 | completed | 2015-06-01 | 2017-10-01 | Galectin Therapeutics Inc. | Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis |
| NCT00110721 | phase2 | terminated | 2005-05-01 | 2007-06-01 | Galectin Therapeutics Inc. | GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer |
FDA applications (0)
No records yet.